Abraham Alahmad, PhD 🔬🧠💊🇫🇷🇺🇸🇸🇾
@scientistabe.bsky.social
Associate Professor of Pharmacology. Expertise on the blood-brain barrier (BBB) and response to hypoxic injury, and glucose metabolism. Also teach pharmacokinetics to PharmD student. Sci-Fi lover, metalhead, retrocomputing. He/Him.
January 2, 2025 at 4:01 PM
You are welcome! Again this is my personal opinion and would like to hear from seasoned colleagues more akin on brain drug delivery. But thing is certain: the headline is too sensational and clickbait. Oh well, PhDComics had it summarized well this issue :)
December 4, 2024 at 12:44 PM
You are welcome! Again this is my personal opinion and would like to hear from seasoned colleagues more akin on brain drug delivery. But thing is certain: the headline is too sensational and clickbait. Oh well, PhDComics had it summarized well this issue :)
My biggest concern? How did the authors ensured samples were taken and maintained under sterile conditions? Nowhere it is written and this is for me some serious concerns. You want samples extracted and frozen in a clean room, otherwise we end up with the same issue than meteorite.
December 2, 2024 at 7:46 PM
My biggest concern? How did the authors ensured samples were taken and maintained under sterile conditions? Nowhere it is written and this is for me some serious concerns. You want samples extracted and frozen in a clean room, otherwise we end up with the same issue than meteorite.
Good morning everyone! Trying to ramp up my activity on this platforms, as the number of notifications has exponentially increased in a week! Let’s start by sharing some cuties 🐈 pic: this is Honey, a 1.5 year old semi-stray cat that became a frequent guest in our family (a younger pic of itself).
November 14, 2024 at 2:18 PM
Good morning everyone! Trying to ramp up my activity on this platforms, as the number of notifications has exponentially increased in a week! Let’s start by sharing some cuties 🐈 pic: this is Honey, a 1.5 year old semi-stray cat that became a frequent guest in our family (a younger pic of itself).
The study has looked at hazard ratio, and seems to me that aside thromboembolic events (~clottings) that Pax seems to reduce, the impact of Pax vs. untreated was mild, and was not causing more harm, and appear not to influence post-COVID outcomes (aka PCCs).
November 13, 2023 at 3:56 PM
The study has looked at hazard ratio, and seems to me that aside thromboembolic events (~clottings) that Pax seems to reduce, the impact of Pax vs. untreated was mild, and was not causing more harm, and appear not to influence post-COVID outcomes (aka PCCs).
The interesting thing is that based on the EHR, they were able to stratify the patients into five groups based on the initiation day of Paxlovid(c) (Nirmatrelvir+Ritonavir) after being Dx with COVID19 by PCR. Note, the two arms (treated with Pax versus not treated) are very homogenous demographics.
November 13, 2023 at 3:52 PM
The interesting thing is that based on the EHR, they were able to stratify the patients into five groups based on the initiation day of Paxlovid(c) (Nirmatrelvir+Ritonavir) after being Dx with COVID19 by PCR. Note, the two arms (treated with Pax versus not treated) are very homogenous demographics.